IMA-950 Drug Asset Due Diligence Report 2026

This IMA-950 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

371

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether IMA-950 can convert its Therapeutic vaccine profile and HLA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	IMA-950 (query alias: IMA-950)
Modality / target	Therapeutic vaccine; HLA; HLA modulators, Immunostimulants
Highest global status	Phase 2
Originator	Immatics Biotechnologies GmbH
Active developers	Cancer Research UK, Immatics Biotechnologies GmbH

The MCP disease footprint includes Glioblastoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03665545	Phase 1/2	Completed	18	Primary endpoint not disclosed in English source
NCT02924038	Phase 1	Terminated	14	Primary endpoint not disclosed in English source
NCT01920191	Phase 1/2	Completed	19	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Phase 1; n=14; evaluation: Not stated in English source. Reported fields: Proportion of Participants Experiencing Regimen Limiting Toxicity (RLT) = 0 % ; Proportion of Participants Experiencing Regimen Limiting Toxicity (RLT) = 0 %

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Phase 1/2; n=19; evaluation: Not stated in English source. Reported fields: mOS = 19 Month

P01.122 Safety, immunogenicity and optimization of the IMA950 multipeptide vaccine combined with Poly-ICLC in newly diagnosed HLA-A2 malignant glioma patients

Phase 1/2; n=19; evaluation: Positive. Reported fields: OS = 21 Month

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

IMA-950 addresses Glioblastoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 371 matched transaction record(s) under the scope “target-level comparable: HLA.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HLA records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-01	Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development	Preclinical	US$75.0M upfront; US$1,530.0M stated total
2026-08-31	Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)	Phase 3	Financial terms not disclosed
2026-08-28	CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO